← Back to Search

GLP-1 Receptor Agonist

Liraglutide for Insulin Resistance

Phase 4
Waitlist Available
Led By Peter D Reaven, MD
Research Sponsored by Phoenix VA Health Care System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks
Awards & highlights

Study Summary

In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Whole Body Insulin Sensitivity (insulin suppression test)
Secondary outcome measures
Adipose tissue arteriole function (vasodilation measurement)
Adipose tissue inflammation measures (e.g., interleukin (IL)-6, and -8, adiponectin, TNF-alpha, nuclear factor-kappa b, gene and protein expression)
Changes in adipose tissue insulin signaling pathway activation (compare insulin signaling pathway activity (e.g., Akt and insulin receptor phosphorylation)
+6 more

Side effects data

From 2017 Phase 4 trial • 100 Patients • NCT02014740
29%
nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Liraglutide
Metformin

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LiraglutideExperimental Treatment1 Intervention
Liraglutide titration up to 1.8 mg/d over approximately 3 weeks
Group II: Sugar pillPlacebo Group1 Intervention
matching placebo and titration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liraglutide
FDA approved

Find a Location

Who is running the clinical trial?

Phoenix VA Health Care SystemLead Sponsor
12 Previous Clinical Trials
1,440 Total Patients Enrolled
1 Trials studying Insulin Resistance
300 Patients Enrolled for Insulin Resistance
Novo Nordisk A/SIndustry Sponsor
1,513 Previous Clinical Trials
2,414,994 Total Patients Enrolled
4 Trials studying Insulin Resistance
127 Patients Enrolled for Insulin Resistance
Peter D Reaven, MDPrincipal InvestigatorCarl T. Hayden Medical Research Foundation
5 Previous Clinical Trials
1,634 Total Patients Enrolled
1 Trials studying Insulin Resistance
300 Patients Enrolled for Insulin Resistance

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans
2013. "The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02403284.
All > Saxenda > Victoza
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top